Blog Archives

Sumitomo Dainippon Pharma Completes the Formation of the Strategic Alliance with Roivant Sciences

Enzyvant Newsrooom | December 2019

Reading Time: 3 minutes

Sumitomo Dainippon Pharma and Roivant Sciences Sign Definitive Agreement for Strategic Alliance

Enzyvant Newsrooom | November 2019

Reading Time: 5 minutes

Enzyvant Appoints Jeb Ledell as Chief Operating Officer

Enzyvant Newsrooom | October 2019

Reading Time: 2 minutes

Enzyvant Announces FDA Acceptance of Biologics License Application (BLA) and Priority Review Status for RVT-802, a Novel Investigational Tissue-Based Regenerative Therapy for Pediatric Congenital Athymia

Enzyvant Newsrooom | June 2019

Reading Time: 5 minutes

Enzyvant’s Investigational Regenerative Treatment (RVT-802) for Congenital Athymia to be Discussed in Symposium, Platform Presentation and Poster Session at Clinical Immunology Society Meeting

Enzyvant Newsrooom | April 2019

Reading Time: 3 minutes

Enzyvant Appoints Industry Veteran Rachelle Jacques as Chief Executive Officer

Enzyvant Newsrooom | February 2019

Reading Time: 2 minutes

Enzyvant Announces Initiation of RVT-802 Rolling BLA Submission for the Treatment of Complete DiGeorge Anomaly

Enzyvant Newsrooom | July 2018

Reading Time: 3 minutes